Sign inJoin waitlistJoin the waitlist

ME

Mitchell Edelson

Associate Professor of Obstetrics and Gynecology · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · · ·

History

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Present

Gynecologic Oncology
Brigham and Women's Hospital
1997–2000
Mount Sinai Medical Center
1993–1997
Sidney Kimmel Medical College at Thomas Jefferson University
1987–1991

Research

Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype
Journal of Pharmacology and Experimental Therapeutics · 1989 · 338 citations
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2016 · Last of 17 authors · Corresponding · 306 citations
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients
Cancer Research · 2004 · 218 citations

NR
Norman Rosenblum
13 papers
Aaron Han
8 papers
CB
Cynthia Bergman
6 papers
Joel Sorosky
6 papers
Mark Shahin
6 papers
RC
Robert Coleman
6 papers
Bill Cliby
5 papers
EB
Elizabeth Burton
5 papers
WT
William Tew
5 papers
AO
Alexander Olawaiye
4 papers
Enrique Hernandez
4 papers
Kathleen Moore
4 papers

Grants

Sidney Kimmel Cancer Center LAPS Institutional Collaboration
National Cancer Institute · UG1
PI · $923.3K · Thomas Jefferson University
2019–2032

Clinical trials

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Site PI · Recruiting · Phase 3
Verastem, Inc.
2024–2031